Immunic, Inc. reported progress in its late-stage development of vidofludimus calcium for multiple sclerosis (MS), with Phase 3 ENSURE trials for relapsing MS on track to deliver top-line data by the end of 2026. The company also plans to start a Phase 3 trial for progressive MS later this year. Leadership expansions include new CEO Erik Lundgren and Chief Medical Officer Michael Panzara, bringing expertise to support clinical development and commercialization. Financially, Immunic is well-capitalized following a private placement and expects to fund operations into late 2027, positioning the company for potential regulatory submissions and commercial launch if trials succeed.
On October 1, Binance recorded the largest daily net inflow of TRX in 99 days, with +79.8 million TRX deposited, significantly above the 30-day average. Despite this spike, the net inflow was driven by a single day rather than a sustained trend, and ...
Ether (ETH) experienced $10.5 million in short-position liquidations within one hour ending at 6:26 p.m. ET on October 4, as its price increased by 1.04% from $2,705 to $2,733. These liquidations occurred across Binance, Bybit, and OKX exchanges, wit...
Bitcoin's price increased by 0.59% within an hour on October 5, moving from $86,052 to $86,564. During this period, $13.96 million in short positions were liquidated across Binance, Bybit, and OKX, while only $10,000 in long positions were liquidated...
Binance liquidated a single Bitcoin short position worth $2.56 million on its perpetual futures market at a price of $86,567. This liquidation occurred on October 4 at 6:16 p.m. ET and involved closing a short trade, which profits from price declines...
France's Schneider Electric is close to acquiring US software company PTC for about $20 billion, according to the Financial Times. The deal could be announced as soon as Monday, though discussions are still ongoing and not guaranteed. PTC, based in B...
